

Xian-Ya Lin,<sup>a</sup> Shu-Ju Liao,<sup>a</sup>  
Ko-Hsin Chin,<sup>b</sup> Hui-Ling Shih,<sup>c</sup>  
Gwan-Han Shen,<sup>d</sup> Andrew H.-J.  
Wang<sup>c</sup> and Shan-Ho Chou<sup>a,b\*</sup>

<sup>a</sup>Institute of Biochemistry, National Chung-Hsing University, Taichung 40227, Taiwan, <sup>b</sup>National Chung-Hsing University Biotechnology Center, National Chung-Hsing University, Taichung 40227, Taiwan, <sup>c</sup>Core Facility for Protein Crystallography, Academia Sinica, Nankang, Taipei, Taiwan, and <sup>d</sup>Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

Correspondence e-mail: shchou@nchu.edu.tw

Received 28 July 2009

Accepted 20 August 2009

## Crystallization and preliminary X-ray diffraction characterization of RpfF, a key DSF synthase from *Stenotrophomonas maltophilia*


*Stenotrophomonas maltophilia* has emerged as a critical nosocomial opportunistic pathogen in the last few years. It is resistant to many clinically useful antibiotics; hence, new ways of combatting this bacterium are essential. Diffusible signal factor (DSF) dependent quorum sensing is a major mechanism of virulence induction in *S. maltophilia*, with RpfF playing a key role in DSF biosynthesis. Inhibiting *S. maltophilia* RpfF (*SmRpfF*) function via small-molecule interference may constitute a new way of treating *S. maltophilia* infection. *SmRpfF* was therefore overexpressed in *Escherichia coli*, purified and crystallized using the hanging-drop vapour-diffusion method. The crystals belonged to the tetragonal space group  $P4_12_12$  or  $P4_32_12$ , with unit-cell parameters  $a = b = 148.51$ ,  $c = 122.82$  Å, and diffracted to a resolution of 2.25 Å.

### 1. Introduction

Antibiotic resistance has developed against virtually every antibiotic employed (Clatworthy *et al.*, 2007). Recently, a new paradigm of targeting bacterial virulence factors rather than bacterial viability has been proposed (Zhang, 2003; Zhang & Dong, 2004; Raffa *et al.*, 2005; Rasmussen & Givskov, 2006a,b; Bjarnsholt & Givskov, 2007; Clatworthy *et al.*, 2007). Since many opportunistic pathogenic bacteria rely on quorum sensing (QS) to regulate expression of their virulence factors, proteins involved in the QS signal network may serve as new targets for developing the next generation of drugs.

*Stenotrophomonas maltophilia* is a newly emerging bacterium that deserves much attention (Johnson & Duckworth, 2008; Looney *et al.*, 2009). The sequencing of its genome has recently been completed (Crossman *et al.*, 2008), revealing an organism with a remarkable capacity for drug and heavy-metal resistance. Similar to *Xanthomonas campestris* (Barber *et al.*, 1997; Slater *et al.*, 2000; Zhang & Dong, 2004; Ryan *et al.*, 2006; Dong *et al.*, 2007; He & Zhang, 2008), *S. maltophilia* contains an *rpf* gene cluster (for regulator of pathogenicity factors) that is believed to be the major determinant for quorum sensing and for control of pathogenicity gene expression (Fouhy *et al.*, 2007). The *rpf* cluster comprises a number of *rpf* genes involved in regulating the synthesis of extracellular enzymes and polysaccharides. Of these *rpf* gene products, RpfF is the key protein responsible for diffusible signal factor (DSF) synthesis (Tang *et al.*, 1991). Importantly, mutation of the *rpfF* gene was found to significantly reduce the tolerance of *S. maltophilia* to many antimicrobial compounds, indicating that *S. maltophilia* RpfF (*SmRpfF*) is a potential target for the discovery of drugs based on this novel principle (Fouhy *et al.*, 2007).


However, in order to target RpfF it is necessary to obtain a more thorough understanding of its tertiary structure. Although RpfF has been found to bear some relatedness to enoyl-CoA hydratase, its structure is still unknown and remains to be determined. In this paper, we report the crystallization and preliminary X-ray diffraction characterization of *SmRpfF*.



## 2. Materials and methods

### 2.1. Cloning, expression and purification

The *rpfF* gene fragment was PCR-amplified directly from a local *S. maltophilia* genome with a forward 5'-*TACTTCCAATCCAATGCTATGTCTGCAGTACGCCCATCA* primer and a reverse 5'-*TTATCCACTTCCAATGTCAGGCCGGGTCGCCATT* primer (the linker sequences are italicized). A ligation-independent cloning (LIC) approach (Aslanidis & de Jong, 1990) was carried out to obtain the desired construct according to a previously published protocol (Wu *et al.*, 2005). The final construct codes for an N-terminal His<sub>6</sub> tag, a 17-amino-acid linker and the *SmRpfF* target protein (289 amino acids) under the control of a T7 promoter. The vector was transformed into *Escherichia coli* BL21 (DE3) C41 host cells, which were grown in LB medium at 310 K until an OD<sub>600</sub> of 0.8 was attained. Overexpression of the His<sub>6</sub>-tagged target protein was induced by the addition of 0.5 mM IPTG at 293 K for 20 h. The cells were harvested, resuspended in equilibration buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl and 5 mM β-mercaptoethanol) and lysed using a microfluidizer (Microfluidics). Most tagged target proteins were present in the soluble fraction (Fig. 1). After centrifugation, the target protein was purified by immobilized metal-affinity chromatography (IMAC) on a nickel column (Sigma) and eluted with a 50–300 mM imidazole gradient in 20 mM Tris-HCl pH 8.0, 500 mM NaCl and 5 mM β-mercaptoethanol. The fractions containing *SmRpfF* were monitored by SDS-PAGE, recombined and dialyzed repeatedly against 20 mM Tris-HCl pH 8.0, 500 mM NaCl and 5 mM β-mercaptoethanol. After buffer exchange, the His<sub>6</sub> tag and linker were cleaved from *SmRpfF* by TEV (tobacco etch virus) protease at 295 K for 16 h and removed by immobilized metal-affinity chromatography (IMAC) on a nickel column (Sigma). For crystallization, *SmRpfF* was further purified by FPLC (ÄKTA, Pharmacia Inc.) on an anion-exchange column (DEAE Sepharose FF). The fractions eluted with 20 mM Tris pH 8.0, 1 M NaCl were combined and dialyzed against 20 mM Tris pH 8.0, 500 mM NaCl and 5 mM β-mercaptoethanol. The final protein (292 amino acids) had greater than 95% purity and contained a non-native tripeptide (Ser-Asn-Ala) followed by the target protein sequence of 289 amino acids (the GenBank accession No. for *SmRpfF* is DQ\_4156711 and the protein ID is ABD594531). SeMet-




**Figure 1** SDS-PAGE monitoring of the overexpression and purification of *SmRpfF*. Lane *M*, molecular-weight marker standards (kDa); lane 1, whole cell lysate before IPTG induction; lane 2, whole cell lysate after IPTG induction; lane 3, purified *SmRpfF* before TEV cleavage; lane 4, purified *SmRpfF* after TEV cleavage.


substituted *SmRpfF* was expressed in a similar way except that the cells were induced in SeMet-containing M9 minimal medium when an OD<sub>600</sub> of 0.8 was reached. The overexpression and purification of SeMet-substituted *SmRpfF* were monitored by SDS-PAGE as shown in Fig. 1.

### 2.2. Crystallization

For crystallization, the protein was concentrated to 4 mg ml<sup>-1</sup> in 20 mM Tris-HCl pH 8.0, 500 mM NaCl and 5 mM β-mercaptoethanol using an Amicon Ultra-10 (Millipore). Screening for crystallization conditions of *SmRpfF* was performed using the sitting-drop vapour-diffusion method in 96-well plates (Hampton Research) at 298 K. 1 μl



(a)



(b)

**Figure 2** Crystal and diffraction pattern of *SmRpfF*. (a) Crystal of *SmRpfF* obtained by the hanging-drop vapour-diffusion method. The final optimized crystallization condition was 0.1 M sodium cacodylate buffer pH 6.5, 0.1 M NaH<sub>2</sub>PO<sub>4</sub> and 1 M sodium acetate. The dimensions of these diamond-shaped crystals were approximately 0.12 × 0.07 × 0.03 mm. (b) Picture of the diffraction pattern of *SmRpfF* collected at the Taiwan NSRRC synchrotron facility (beamline 13B1) from a flash-frozen crystal in 20% (v/v) glycerol cryoprotectant. The exposure time was 10 s and the oscillation range was 0.5° per frame, with a crystal-to-detector distance of 220 mm.

**Table 1**  
Summary of native and Se-MAD crystallographic data for *SmRpPf*.

Values in parentheses are for the outermost shell.

	Infection	High remote	Native
Beamline	NSRRC BL13B1		
Wavelength (Å)	0.97913	0.96391	0.97622
Space group	$P4_12_12$ or $P4_32_12$	$P4_12_12$ or $P4_32_12$	$P4_12_12$ or $P4_32_12$
Unit-cell parameters (Å)	$a = b = 147.79$ , $c = 122.04$	$a = b = 147.78$ , $c = 122.04$	$a = b = 148.51$ , $c = 122.82$
Resolution range (Å)	30–3.46 (3.58–3.46)	30–3.46 (3.58–3.46)	30–2.25 (2.33–2.25)
Unique observations	18195 (1739)	18153 (1720)	64872 (6401)
Redundancy	9.3 (8.8)	9.3 (8.9)	7.0 (4.9)
Completeness (%)	99.7 (97.9)	99.6 (97.6)	98.8 (98.7)
$R_{\text{merge}}^\dagger$ (%)	17.7 (62.8)	14.3 (63.5)	6.9 (51.9)
$\langle I/\sigma(I) \rangle$	13.1 (3.1)	13.8 (3.1)	22.4 (3.1)

$^\dagger R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$ , where  $I_i(hkl)$  is the intensity of the  $i$ th observation of reflection  $hkl$  and  $\langle I(hkl) \rangle$  is the average intensity of redundant measurements of reflection  $hkl$ .

drops comprising equal volumes of protein solution and reservoir solution were equilibrated against 50  $\mu$ l reservoir solution. Initial screens, including Hampton Research sparse-matrix Crystal Screens 1 and 2, a systematic PEG–pH screen and the PEG/Ion Screen, were performed using a Gilson C240 crystallization workstation. Diamond-shaped crystals appeared in 3 d from a reservoir solution comprising 0.1 M sodium cacodylate buffer pH 6.5, 0.1 M  $\text{NaH}_2\text{PO}_4$  and 1 M sodium acetate. Crystals suitable for diffraction experiments were grown by mixing 1.5  $\mu$ l protein solution with 1.5  $\mu$ l reagent solution and equilibrating against 500  $\mu$ l reservoir solution. The crystals reached maximum dimensions of 0.12  $\times$  0.07  $\times$  0.03 mm after one week (Fig. 2a).

### 2.3. Data collection

The *SmRpPf* crystals were soaked in a cryoprotectant solution comprising reservoir solution plus 20% (v/v) glycerol. X-ray diffraction data were collected on National Synchrotron Radiation Research Center (NSRRC) beamline 13B1 in Taiwan. A native data set was collected to 2.25 Å resolution and a two-wavelength multiple anomalous dispersion (MAD) data set was collected to a resolution of 3.46 Å. The data were indexed and integrated using the *HKL-2000* processing software (Otwinowski & Minor, 1997), yielding three data sets, each 99% complete, with  $R_{\text{merge}}$  values in the range 6.9–17.7%. The *SmRpPf* crystals belonged to the tetragonal space group  $P4_12_12$  or  $P4_32_12$ , which cannot be discriminated until the final structure has been solved. The data-collection statistics are summarized in Table 1 and an X-ray diffraction image is shown in Fig. 2(b).

### 3. Results and discussion

In this manuscript, we report the successful cloning, expression and crystallization of RpPf from *S. maltophilia*. We have also obtained high-resolution X-ray diffraction data from native crystals and moderate-resolution data from SeMet-substituted crystals of *SmRpPf* (Table 1 and Fig. 2). Analyses of the diffraction intensities indicated that the space group was either  $P4_12_12$  or  $P4_32_12$ , with unit-cell parameters  $a = b = 147.79$ ,  $c = 122.04$  Å. The Matthews coefficient  $V_M$

(Matthews, 1968) suggested the presence of three, four or five *SmRpPf* protein molecules per asymmetric unit, with solvent contents of 63.64, 51.52 or 39.40%, respectively. There are a total of 12 methionine residues in *SmRpPf*. Their substitution by SeMet should provide sufficient phasing power to solve the *SmRpPf* structure. In fact, we have already obtained the preliminary Se substructure (data not shown). We are confident that we have the data required for structure solution and work towards solution is currently ongoing.

This work was supported by an Academic Excellence Pursuit grant from the Ministry of Education and by the National Science Council, Taiwan (grant 97-2113-M005-005-MY3) to S-HC. We appreciate the Structural Genomics Database service provided by the GMBD Bioinformatics Core (<http://www.tbi.org.tw>), NRPDM, Taiwan. We would also like to thank the Core Facilities for Protein X-ray Crystallography in the Academia Sinica, Taiwan for help in crystal screening and the National Synchrotron Radiation Research Center (NSRRC) in Taiwan and the SPring-8 Synchrotron facility in Japan for assistance during X-ray data collection. The National Synchrotron Radiation Research Center is a user facility supported by the National Science Council, Taiwan and the Protein Crystallography Facility is supported by the National Research Program for Genomic Medicine, Taiwan.

### References

- Aslanidis, C. & de Jong, P. J. (1990). *Nucleic Acids Res.* **18**, 6069–6074.  
 Barber, C. E., Tang, J. L., Feng, J.-X., Pan, M. Q., Wilson, T. J. G., Slater, H., Dow, J. M., Williams, P. & Daniels, M. J. (1997). *Mol. Microbiol.* **24**, 555–566.  
 Bjarnsholt, T. & Givskov, M. (2007). *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **362**, 1213–1222.  
 Clatworthy, A. E., Pierson, E. & Hung, D. T. (2007). *Nature Chem. Biol.* **3**, 541–548.  
 Crossman, L. C. *et al.* (2008). *Genome Biol.* **9**, R74.  
 Dong, Y.-H., Wang, L.-H. & Zhang, L.-H. (2007). *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **362**, 1201–1211.  
 Fouhy, Y., Scanlon, K., Schouest, K., Spillane, C., Crossman, L., Avison, M. B., Ryan, R. P. & Dow, J. M. (2007). *J. Bacteriol.* **189**, 4964–4968.  
 He, Y.-W. & Zhang, L.-H. (2008). *FEMS Microbiol. Rev.* **32**, 842–857.  
 Johnson, A. P. & Duckworth, G. J. (2008). *Br. Med. J.* **336**, 1322.  
 Looney, W. J., Narita, M. & Muhlemann, K. (2009). *Lancet Infect. Dis.* **9**, 312–323.  
 Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.  
 Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.  
 Raffa, R. B., Iannuzzo, J. R., Levine, D. R., Saeid, K. K., Schwartz, R. C., Sucic, N. T., Terieckij, O. D. & Young, J. M. (2005). *J. Pharmacol. Exp. Ther.* **312**, 417–423.  
 Rasmussen, T. B. & Givskov, M. (2006a). *Int. J. Med. Microbiol.* **296**, 149–161.  
 Rasmussen, T. B. & Givskov, M. (2006b). *Microbiology*, **152**, 895–904.  
 Ryan, R. P., Fouhy, Y., Lucey, J. F., Crossman, L. C., Spiro, S., He, Y.-W., Zhang, L.-H., Heeb, S., Camara, M., Williams, P. & Dow, J. M. (2006). *Proc. Natl Acad. Sci. USA*, **103**, 6712–6717.  
 Slater, H., Alvarez-Morales, A., Barber, C. E., Daniels, M. J. & Dow, J. M. (2000). *Mol. Microbiol.* **38**, 986–1003.  
 Tang, J. L., Liu, Y. N., Barber, C. E., Dow, J. M., Wootton, J. C. & Daniels, M. J. (1991). *Mol. Gen. Genet.* **226**, 409–417.  
 Wu, Y.-Y., Chin, K.-H., Chou, C.-C., Lee, C.-C., Shr, H.-L., Gao, F. P., Lyu, P.-C., Wang, A. H.-J. & Chou, S.-H. (2005). *Acta Cryst.* **F61**, 902–905.  
 Zhang, L.-H. (2003). *Trends Plant. Sci.* **8**, 238–244.  
 Zhang, L.-H. & Dong, Y.-H. (2004). *Mol. Microbiol.* **53**, 1563–1571.